Number Of Products Approved By Food And Drug Administration

No definition available.

Name:	aqst_NumberOfProductsApprovedByFoodAndDrugAdministration
Namespace Prefix:	aqst_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Sale of Stock, Aggregate Offering Price

+ References

No definition available.

+ Details

Name:	aqst_SaleOfStockAggregateOfferingPrice
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sale Of Stock, Remaining Amount Available For Offering

+ References

No definition available.

+ Details

Name:	aqst_SaleOfStockRemainingAmountAvailableForOffering
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585

+ Details

Name:	us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=aqst_LicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=aqst_StandAloneProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=aqst_EquityDistributionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=aqst_AtTheMarketOfferingAmendmentOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=aqst_AtTheMarketOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Company Overview and Basis of Presentation (Details)				3 Months Ended		16 Months Ended
Company Overview and Basis of Presentation (Details)	Mar. 31, 2022 USD ($)	Mar. 26, 2021 USD ($)	Sep. 11, 2019 USD ($)	Mar. 31, 2022 USD ($) product shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2022 USD ($) shares
Subsidiary, Sale of Stock [Line Items]
Number of products approved by Food and Drug Administration \| product				5
Licensed Product
Subsidiary, Sale of Stock [Line Items]
Number of products approved by Food and Drug Administration \| product				4
Stand Alone Product
Subsidiary, Sale of Stock [Line Items]
Number of products approved by Food and Drug Administration \| product				1
Equity Distribution Agreement
Subsidiary, Sale of Stock [Line Items]
Sale of stock, aggregate offering price			$ 25,000,000
At-the-Market Offering, Amendment No. 1 \| Maximum
Subsidiary, Sale of Stock [Line Items]
Sale of stock, aggregate offering price		$ 50,000,000
At-the-Market Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued in transaction (in shares) \| shares				391,652	1,672,104	7,873,071
Consideration received on sale of stock				$ 1,298,000	$ 9,891,000	$ 37,131,000
Payments for stock issuance costs				$ 62,000	$ 306,000	$ 1,826,000
Remaining amount available for offering	$ 36,043,000